ACCESS AND REIMBURSEMENTRESOURCES
To help guide your patients throughout the access process
Lundbeck is committed to patient access and providing support through a VYEPTI CONNECT liaison or a Field Reimbursement Specialist. Below are resources that may be helpful.
files selected
ClearComplete this enrollment form to begin the benefits investigation process.
Information on how your eligible commercially insured patients can enroll and the program's eligibility requirements.
Information that may be helpful when submitting claims for VYEPTI.
Information about acquiring VYEPTI under the medical benefit and the settings where it can be infused.
Information that may help you organize material that may be needed to complete a PA for VYEPTI.
Information about what may be needed to complete a Letter of Medical Necessity.
Information about what may be needed to complete a Letter of Appeal.
Information about what may be needed to complete a Letter of Medical Exception.
Download and fill out patient information for transition to a new infusion location.
Healthcare providers with patients who do not wish to enroll in VYEPTI CONNECT, but still want access support from a Field Reimbursement Specialist, should download and submit this form.
Healthcare providers in California with patients who do not wish to enroll in VYEPTI CONNECT, but still want access support from a Field Reimbursement Specialist, should download and submit this form in addition to the Healthcare Provider Attestation; authorization can be sent via fax.
Review the Terms and Conditions for the VYEPTI CONNECT Copay Assistance Program.
The resources on this page are for informational purposes only and are not intended to provide reimbursement or legal advice. The information presented here does not guarantee payment or coverage.
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
VYEPTI is indicated for the preventive treatment of migraine in adults.
Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Full Prescribing Information and Patient Information.
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
VYEPTI is indicated for the preventive treatment of migraine in adults.
Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Full Prescribing Information and Patient Information.